Harvard Medical School and Cellectricon collaborates Around Whole-Genome RNAi Screening Technology
News Nov 26, 2008
Cellectricon has announced its collaboration with Harvard Medical School, the ICCB-Longwood Screening Facility. Harvard Medical School (ICCB-L) will utilize the Cellaxess®HT system, a system for high throughput transfection enabling reagent-free delivery of genetic material to a wide range of biologically relevant cell types.
“We are excited about the collaboration with Cellectricon and the opportunity we have to evaluate Cellaxess®HT for genome-wide RNAi delivery to biologically relevant cell types”, says Caroline Shamu, Director of ICCB-L.
“Cellectricon is extremely proud to collaborate with a world-class research institution such as Harvard Medical School (ICCB-L)”, says Jonas Ohlsson, CEO at Cellectricon. We look forward to jointly advance the RNAi research area by our technology, as we’re confident that Cellaxess®HT will aid in the generation of more relevant results from RNAi screening campaigns.”
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Improved Method for Isolating Extracellular RNANews
In a breakthrough that could lead to powerful new ways to diagnose and track a wide range of medical conditions, scientists at The Rockefeller University have devised an improved method for isolating and identifying tiny fragments of RNA in human blood products.READ MORE